Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non‐transfusion‐dependent β‐thalassaemia.

GLO:1XW/15jul21:bjh17479-fig-0001.jpg PHOTO (COLOR): 1 Individual haemoglobin (Hb) changes during the trial for patients with -thalassaemia. Treatment-emergent adverse events (AEs) observed in patients with non-transfusion-dependent (NTD) -thalassaemia undergoing treatment with bitopertin. Keywords: bitopertin; haem; iron; reactive oxygen species; -thalassemia EN bitopertin haem iron reactive oxygen species -thalassemia 474 477 4 07/19/21 20210715 NES 210715 Bitopertin is a small molecule selective inhibitor of glycine transporter 1 (GlyT1), initially developed to increase brain extracellular levels of glycine in the vicinity of neuronal I N i -methyl-D-aspartate receptors for the treatment of schizophrenia. [Extracted from the article]